特利加压素控制肝癌肝切除术后腹腔积液形成的前瞻性研究

Effects of terlipressin in the management of ascites after hepatectomy: a prospective trial

  • 摘要: 目的 探讨特利加压素控制肝癌肝切除术后腹腔积液形成的临床疗效。方法 前瞻性分析 2010年1月至2011年1月华中科技大学同济医学院附属协和医院符合标准的54例肝癌患者的临床资料,按照随机数字表法分为研究组(28例)和对照组(26例)。研究组予以特利加压素和白蛋白治疗,对照组予以呋塞米和白蛋白治疗,比较两组患者肝切除术后腹腔积液量、尿量和肾功能、电解质平衡、术后恢复情况以及并发症发生率。计量资料采用两样本t检验,计数资料采用χ2检验或Fisher确切概率法。结果 研究组患者肝癌肝切除术后腹腔积液平均每天最大引流量为(351±174)ml,明显低于对照组的(551± 233)ml,两组比较,差异有统计学意义(t=3.604,P<0.05)。研究组患者治疗后1、3d的尿量均多于对照组,两组比较,差异有统计学意义(t=5.816,2.722,P<0.05)。对照组1例患者出现肝肾综合征,其余患者的肾功能均无异常。研究组有11%(3/28)的患者出现电解质紊乱,对照组为35%(9/26),两组比较,差异有统计学意义(χ2=4.456,P<0.05)。研究组患者术后ICU滞留时间为(22±12)h,较对照组的(23±10)h 短。研究组患者平均肛门排气时间为(68±24)h,较对照组的(76±28)h短,但两组比较,差异无统计学意义(t=0.331,1.130,P>0.05)。研究组患者的平均引流管拔管时间和住院时间分别为(102±42)h和 (15±4)d,明显短于对照组的(140±50)h和(18±5)d,两组比较,差异有统计学意义(t=3.032,2.443, P<0.05)。研究组1例患者出现血压升高,对照组1例患者出现心率失常,两组均无心肌梗死、肠坏死以及外周组织缺血等并发症出现,两组患者的不良反应发生率分别为4%(1/28)和4%(1/26),两组比较,差异无统计学意义(P>0.05)。结论 特利加压素能有效控制肝癌肝切除术后腹腔积液的形成,对电解质平衡影响较小并有利于患者术后恢复。

     

    Abstract:

    ObjectiveTo investigate the efficacy of terlipressin in the management of ascites after hepatectomy. Methods Fifty four patients with hepatic cancer who were admitted to the Union Hospital of Tongji Medical College from January 2010 to January 2011 were randomly divided into the research group (28 patients) and control group (26 patients) according to the random number table. Patients in the research group were treated by the terlipressin and albumin, and patients in the control group were treated by furosemide and albumin. The volume of ascites, urine output, renal function, electrolyte balance, recovery after hepatectomy and complications of the 2 groups were investigated. All data were analyzed by the t test, chi square test or Fisher exact probability. Results The volume of postoperative maximum drainage was (351±174)ml in the research group, which was significantly lesser than (551±233)ml in the control group ( t= 3.604, P <0.05). The total urine output of the research group was significantly higher than that of the control group at postoperative day 1 and day 3 ( t=5.816, 2.722, P <0.05). All patients had normal renal function except 1 patient was complicated by hepatorenal syndrome in the control group. Electrolyte imbalance was observed in 3 patients (11%) in the research group and 9 patients (35%) in the control group, with a significant difference (χ 2=4.456, P <0.05). The postoperative time of intensive care unit stay and the anal exsufflation time of the research group were (22±12)hours and (68±24)hours, which were similar to (23±10)hours and (76±28)hours of the control group ( t=0.331, 1.130, P > 0.05). The abdominal drainage tube removal time and hospital stay of the research group were (102±42)hours and (15±4)days, which were significantly shorter than (140±50)hours and (18±5)days ( t=3.032, 2.443, P <0.05). There were 1 patient in the research group complicated with high blood pressure and 1 patient in the control group with cardiac arrhythmia. The incidences of adverse reaction were 4%(1/28) in the research group and 4%(1/26) in the control group, with no significant difference ( P >0.05). Conclusion Terlipressin is effective in the management of ascites after hepatectomy, has less effect on electrolyte balance and is beneficial to quick recovery.

     

/

返回文章
返回